Quantcast

Latest Small interfering RNA Stories

2014-07-08 12:28:30

GAITHERSBURG, Md., July 8, 2014 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled "Multi-Targeted RNAi Therapeutics for Scarless Wound Healing of Skin" (US 8,735,567 B2, PCT/US2008/012498). This USPTO issuance, combined with a similar success for a Chinese patent (ZL 200880124132.8) provides a solid foundation and protection for the...

2014-06-18 23:13:01

PeptiMed, a biopharmaceutical company focused on novel mechanisms of drug delivery, is pleased to announce the allowance of its claims for a targeted elastin-like polypeptide (ELP) nanoparticle for delivery of nucleotide therapeutic agents. Madison, Wisconsin (PRWEB) June 18, 2014 PeptiMed announced today that it was awarded United States patent No. 8,680,045, entitled, “Compositions of a peptide targeting system for treating cancer.” The invention describes a protein nanoparticle...

2014-06-17 08:29:28

LA JOLLA, Calif., June 17, 2014 /PRNewswire/ -- Avidity NanoMedicines, a biopharmaceutical company pioneering development of the Antibody-siRNA Complex (ARC(TM)) as a new therapeutic class, announced today the issuance of two new U.S. patents. ARCs(TM) combine the potency and specificity of biologics with a nucleic acid-based payload, representing a breakthrough approach to the targeted delivery of nucleic acid-based medicines. The two new U.S. patents arose out of pioneering work...

2014-05-28 23:08:58

Transparency Market Research added a new report "Global RNAI Technology Market: Analysis, Share, Size, Growth and Forecast 2010-2017" to its report store. Browse the full report: http://www.transparencymarketresearch.com/rnai-technology-market.html Albany, New York (PRWEB) May 28, 2014 The market for RNAi Technology will gain traction due to its applicability in various fields such as drug discovery, agriculture, therapeutics and others. RNAi Technology is classified as micro...

2014-05-22 08:29:07

WESTBOROUGH, Mass., May 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd?rxRNA®). The patent, titled "Reduced Size Self-Delivering RNAi...

2014-04-24 08:25:01

DUBLIN, Apr. 24, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5lsv8t/global_rnai_drug ) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA...

2014-04-21 23:02:46

Transparency Market Research Report Added "Research Report on Micro-RNA Market Analysis, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/micro-rna-market.html. Albany, New York, USA (PRWEB) April 21, 2014 Transparency Market Research Reports included a detailed market survey and analysis trends on “Micro-RNA Market”. This report also includes more info about basic overview of the industry including definitions,...

2014-02-24 12:27:26

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, today announced it will present at BIOCOM's Global Life Science Partnering Conference being held on February 26 and 27, 2014 at the Lodge in Torrey Pines, La Jolla, California. In addition to providing an update on its flagship program targeting transthyretin (TTR)-mediated amyloidosis, Arcturus will present data for its proprietary LUNAR(TM) delivery...

2014-02-05 12:29:08

LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire/ -- Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that Arthur A. Levin, Ph.D., has joined the company as Executive Vice President of Research and Development. In this role, Dr. Levin will be responsible for leading Avidity's research and development organization and overseeing advancement of its drug pipeline. "Art brings an...

2014-02-04 23:24:31

A team of international researchers say “turning off” the gene for mesothelin slows the spread of mesothelioma and sensitizes cells to cisplatin therapy. Raleigh, NC (PRWEB) February 04, 2014 New research published in the online open-access medical journal PLoS One and reported by Surviving Mesothelioma suggests that “knocking down” mesothelin production with synthetic RNA may offer a novel approach to treating malignant pleural mesothelioma. Mesothelioma is one of several cancers...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related